Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 10/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.40 |
| ▸ | CDK5 | Q00535 | 6/20 | 0.38 |
| ▸ | CDK5R1 | Q15078 | 5/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CDK7 | P50613 | 10/20 | 0.33 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.33 |
| ▸ | CCNH | P51946 | 5/20 | 0.33 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.33 |
| ▸ | CDK1 | P06493 | 4/20 | 0.33 |
| ▸ | CDK9 | P50750 | 4/20 | 0.33 |
| ▸ | CDK4 | P11802 | 3/20 | 0.33 |
| ▸ | CCND1 | P24385 | 3/20 | 0.33 |
| ▸ | CDK8 | P49336 | 3/20 | 0.33 |
| ▸ | CDK6 | Q00534 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20971704 | 0.85 | MAPT (0.54) | CDK2CDK5CDK5R1KDM4EALDH1A1 | |
| SCHEMBL26974008 | 0.85 | CDK2 (0.40) | CDK2CDK5CDK5R1KDM4EALDH1A1 | |
| SCHEMBL23181597 | 0.83 | KDM4E (0.40) | CDK2CDK5CDK5R1KDM4EALDH1A1 | |
| SCHEMBL29344706 | 0.83 | CDK2 (0.37) | CDK2PDE10ACDK5CDK5R1KDM4E | |
| SCHEMBL24964837 | 0.83 | CDK2 (0.36) | CDK2PDE10ACDK5CDK5R1KDM4E | |
| SCHEMBL17625103 | 0.81 | CDK2 (0.40) | CDK2CDK5CDK5R1GSK3BLMNA | |
| SCHEMBL23530579 | 0.81 | CDK2 (0.37) | CDK2CDK5CDK5R1GSK3BLMNA | |
| SCHEMBL29344761 | 0.81 | CDK2 (0.35) | CDK2PDE10AKDM4EALDH1A1MAPT | |
| SCHEMBL16072122 | 0.80 | CDK2 (0.36) | CDK2CDK5CDK5R1GSK3BLMNA | |
| SCHEMBL31064145 | 0.80 | LMNA (0.39) | CDK2CDK5CDK5R1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 164 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109988172-B | Synthesis method of pyrazolo [1,5-A ] pyrimidine heterocyclic compound and derivative | 石家庄学院 | 2020-09-29 | — | — | CN | claimed |
| EP-4717312-A1 | PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES USEFUL AS A MEDICAMENT | Perha Pharmaceuticals (FR) | 2026-04-01 | — | — | EP | disclosed |
| EP-4710923-A2 | INDOLE AHR INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-RE50776-E1 | Inhibitors of cyclin-dependent kinases | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-02-03 | — | — | US | disclosed |
| EP-3612030-B1 | INDOLE AHR INHIBITORS AND USES THEREOF | IKENA ONCOLOGY INC (US) | 2025-12-24 | — | — | EP | disclosed |
| US-12473303-B2 | 4-[[(7-aminopyrazolo[1,5-a]pyrimidin-5-yl)amino methyl]piperidin-3-ol compounds and their therapeutic use | Carrick Therapeutics Limited (IE) | 2025-11-18 | — | — | US | disclosed |
| US-20250122205-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2025-04-17 | — | — | US | disclosed |
| WO-2025067540-A1 | PYRAZOLOTRIAZINE AND PYRAZOLOPYRIMIDINE DERIVATIVES, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USE THEREOF | 中国科学院上海药物研究所 | 2025-04-03 | — | — | WO | disclosed |
| CN-119707984-A | Pyrazolotriazine and pyrazolopyrimidine derivative, preparation method thereof, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2025-03-28 | — | — | CN | disclosed |
| CN-114929708-B | 4- [ [ (7-Aminopyrazolo [1,5-a ] pyrimidin-5-yl) amino ] methyl ] piperidin-3-ol compounds and their therapeutic uses | 卡里克治疗有限公司 | 2025-02-18 | — | — | CN | disclosed |
| US-20070054906-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2007-03-08 | — | — | US | disclosed |
| US-20070054906-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2007-03-08 | — | — | US | disclosed |
| US-20070054925-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2007-03-08 | — | — | US | disclosed |
| US-20070054925-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2007-03-08 | — | — | US | disclosed |
| US-20070037824-A1 | Enzyme inhibitors from pyrazolo[1,5a]pyrimidine as enzyme inhibitors | SCHERING CORPORATION | 2007-02-15 | — | — | US | disclosed |
| US-20070037824-A1 | Enzyme inhibitors from pyrazolo[1,5a]pyrimidine as enzyme inhibitors | SCHERING CORPORATION | 2007-02-15 | — | — | US | disclosed |
| US-7161003-B1 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2007-01-09 | — | — | US | disclosed |
| US-7161003-B1 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2007-01-09 | — | — | US | disclosed |
| EP-1608652-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN MEDICINE | Vernalis (Cambridge) Limited (GB) | 2005-12-28 | — | — | EP | disclosed |
| WO-2004087707-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN MEDICINE | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054925-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | CDK2, CDK1, CDKN1A | CDK2 1/4885PDE10A 1590/4885CDK5 5/4885 |
| US-20250122205-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | AHR, ARNT, IDO1 | CDK2 1444/4885PDE10A 2875/4885CDK5 1931/4885 |
| US-20070037824-A1 | Enzyme inhibitors from pyrazolo[1,5a]pyrimidine as enzyme inhibitors | CDK2, CDK5, CDKN1A | CDK2 1/4885PDE10A 1177/4885CDK5 2/4885 |
| US-12473303-B2 | 4-[[(7-aminopyrazolo[1,5-a]pyrimidin-5-yl)amino methyl]piperidin-3-ol compounds and their therapeutic use | CDK3, CDK1, CDK2 | CDK2 3/4885PDE10A 3047/4885CDK5 25/4885 |
| US-20070054906-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | CDK2, CDK1, CDKN1A | CDK2 1/4885PDE10A 1590/4885CDK5 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.